

#### **Savaysa**

Patient Information:			
Name:			
Member ID:			
Address:			
City, State, Zip:			
Date of Birth:			
Prescriber Information:			
Name:			
NPI:			
Phone Number:			
Fax Number			
Address:			
City, State, Zip:			
Requested Medication			
Rx Name:			
Rx Strength			
Rx Quantity:			
Rx Frequency:			
Rx Route of			
Administration:			
Diagnosis and ICD Code:			
prescribed a medication for your quantities can be provided. Plea Upon receipt of the complete  SECTION A: Please no requests. Pharmacy primedications that are no	efit requires that we review certain requests for coverage with the part patient that requires Prior Authorization before benefit coverage or consecutive the following questions then fax this form to the toll-free red form, prescription benefit coverage will be determined based on the that supporting clinical documentation is required or authorization reviews can be subject to trial with the tile that supporting clinical documentation is required or authorization reviews can be subject to trial with the tile that supporting clinical documentation is required or authorization reviews can be subject to trial with the tile that supporting clinical documentation is required or authorization reviews can be subject to trial with the tile that supporting clinical documentation is required or authorization reviews can be subject to trial with the tile that supporting clinical documentation is required or authorization reviews and the prior to the toll-free representation to the toll-	overage of number lise on the pland d for <b>AL</b> addition o chance	additional ted below. an's rules. LPA nal ge based
1 Is the patient curre [If no, skip to quest	ntly receiving the requested medication? ion 8.]	Yes	No
2 Has the patient bee [If yes, skip to ques	en receiving medication samples for the requested medication? stion 7.]	Yes	No
the current plan?	ave a previously approved prior authorization (PA) on file with nt does NOT have a previously approved PA on file for the	Yes	No

If you have any questions, call: 1-888-258-8250

Version 07.2025

	requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 8.]		
4	Has the patient been on established therapy for at least 6 months? [If no, skip to question 10.]	Yes	No
5	Has documentation been submitted to confirm that there is a beneficial clinical response of the patient's condition which has stabilized or improved based upon the prescriber's assessment? ACTION REQUIRED: Submit supporting documentation.  [If no, no further questions.]	Yes	No
6	What is the diagnosis or indication? [] Atrial fibrillation (or atrial flutter) (If checked, no further questions)		
	[] Treatment of deep vein thrombosis or pulmonary embolism (If checked, no further questions)		
	[] Prevention of deep vein thrombosis in a patient undergoing hip replacement surgery (If checked, no further questions)		
	[] Treatment or prevention of other thromboembolic-related conditions. Note: Examples of other thromboembolic-related conditions include superficial vein thrombosis, splanchnic vein thrombosis, hepatic vein thrombosis, or prophylaxis of venous thromboembolism in a high-risk patient. (If checked, no further questions)		
	[] Prevention of venous thromboembolism in an acutely ill medical patient (If checked, no further questions)		
	[] Other (If checked, no further questions)		
7	Has documentation been submitted to confirm that there is a beneficial clinical response of the patient's condition which has stabilized or improved based upon the prescriber's assessment? ACTION REQUIRED: Submit supporting documentation.  [If no, no further questions.]	Yes	No
8	Is the patient greater than or equal to 18 year(s) of age? [If no, no further questions.]	Yes	No
9	What is the diagnosis or indication? [] Atrial fibrillation (or atrial flutter) (If checked, go to 12)		
	[] Treatment of deep vein thrombosis or pulmonary embolism (If checked, go to 15)		
	[] Prevention of deep vein thrombosis in a patient undergoing hip replacement surgery (If checked, go to 20)		

If you have any questions, call: 1-888-258-8250

	[] Treatment or prevention of other thromboembolic-related conditions Note: Examples of other thromboembolic-related conditions include superficial vein thrombosis, splanchnic vein thrombosis, hepatic vein thrombosis, or prophylaxis of venous thromboembolism in a high-risk patient. (If checked, go to 21)		
	[] Prevention of venous thromboembolism in an acutely ill medical patient (If checked, no further questions)		
	[] Other (If checked, no further questions)		
10	Is the patient greater than or equal to 18 year(s) of age? [If no, no further questions.]	Yes	No
11	What is the diagnosis or indication? [] Atrial fibrillation (or atrial flutter) (If checked, go to 12)		
	[] Treatment of deep vein thrombosis or pulmonary embolism (If checked, go to 15)		
	[] Prevention of deep vein thrombosis in a patient undergoing hip replacement surgery (If checked, no further questions)		
	[] Treatment or prevention of other thromboembolic-related conditions. Note: Examples of other thromboembolic-related conditions include superficial vein thrombosis, splanchnic vein thrombosis, hepatic vein thrombosis, or prophylaxis of venous thromboembolism in a high-risk patient. (If checked, go to 21)		
	[] Prevention of venous thromboembolism in an acutely ill medical patient (If checked, no further questions)		
	[] Other (If checked, no further questions)		
12	Does the patient have a documented diagnosis of nonvalvular atrial fibrillation? [If no, no further questions.]	Yes	No
13	Does the patient have an estimated creatinine clearance LESS THAN OR EQUAL TO 95 ml/min within the last 90 days? [If no, no further questions.]	Yes	No
14	Does the requested dose exceed 60mg (1 tablet) daily? [If yes, no further questions.] [If no, skip to question 17.]	Yes	No
15	Does the member have a documented diagnosis of a deep vein thrombosis or pulmonary embolism? [If no, no further questions.]	Yes	No
16	Has documentation been submitted to confirm that the patient has received 5 to 10 days of initial therapy with a parenteral anticoagulant prior to initiating the requested medication? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No

If you have any questions, call: 1-888-258-8250



17	Has documentation been submitted to confirm that the patient have previous trial and failure with Eliquis and dabigatran for at least 30 days unless intolerant or contraindicated? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
18	Does the patient have an active pathological bleed? [If yes, no further questions.]	Yes	No
19	Has the patient been evaluated for significant drug interactions with other anticoagulants, antiplatelets, thrombolytics, serotonin norepinephrine reuptake inhibitors (SNRI), selective serotonin reuptake inhibitors (SSRI), rifampin, etc.? [No further questions.]	Yes	No
20	Has documentation been submitted to confirm that the patient has previous trial and failure with Eliquis and dabigatran unless intolerant or contraindicated? ACTION REQUIRED: Submit supporting documentation. [No further questions.]	Yes	No
21	Has documentation been submitted to confirm that the patient has previous trial and failure with Eliquis and dabigatran unless intolerant or contraindicated? ACTION REQUIRED: Submit supporting documentation.	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

#### FAX COMPLETED FORM TO: 1-833-896-0656

**Disclaimer:** An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

**Confidentiality:** The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any questions, call: 1-888-258-8250

Version 07.2025